https://www.nasdaq.com/press-release/acasti-pharma-to-present-at-the-h.c.-wainwright-bioconnect-2022-conference-2022-01-03
https://www.nasdaq.com/press-release/acasti-pharma-announces-interim-data-meets-all-primary-endpoints-for-pivotal-pk-study
https://www.nasdaq.com/press-release/acasti-pharma-ceo-to-participate-in-the-benzinga-all-access-event-on-december-2nd
https://www.nasdaq.com/press-release/acasti-pharma-announces-annual-stock-option-grants-2021-11-12
https://www.nasdaq.com/press-release/acasti-pharma-to-present-at-the-q4-investor-summit-on-november-16th-2021-11-11
https://www.nasdaq.com/press-release/acasti-pharma-provides-business-update-for-the-second-quarter-of-fiscal-2022-2021-11
https://www.nasdaq.com/press-release/acasti-pharma-schedules-second-quarter-fiscal-2022-business-update-conference-call
https://www.nasdaq.com/press-release/acasti-pharma-awarded-composition-of-matter-patents-for-gtx-101-in-europe-china-and
https://www.nasdaq.com/press-release/acasti-pharma-announces-initiation-of-pharmacokinetic-bridging-study-for-gtx-104-the
https://www.nasdaq.com/press-release/acasti-pharma-provides-update-following-acquisition-of-grace-therapeutics-and-regains
https://www.nasdaq.com/press-release/acasti-pharma-to-present-at-the-oppenheimer-fall-healthcare-summit-on-september-21s
https://www.nasdaq.com/press-release/acasti-pharma-to-present-at-the-h.c.-wainwright-23rd-annual-global-investment
https://www.nasdaq.com/press-release/acasti-pharma-announces-successful-completion-of-its-merger-with-grace-therapeutics
https://www.nasdaq.com/press-release/acasti-pharma-provides-business-update-for-the-first-quarter-of-fiscal-2022-2021-08
https://www.nasdaq.com/press-release/reminder%3a-acasti-pharma-to-host-conference-call-on-august-4th-at-1%3a00-pm-et-to
https://www.nasdaq.com/press-release/acasti-pharma-schedules-conference-call-for-august-4th-at-1%3a00-pm-et-to-discuss
https://www.nasdaq.com/press-release/acasti-pharma-provides-fiscal-2021-year-end-business-update-2021-06-22
https://www.nasdaq.com/press-release/acasti-intends-to-request-hearing-before-nasdaq-panel-to-present-plan-of-compliance
https://www.nasdaq.com/press-release/acasti-announces-definitive-agreement-to-acquire-grace-therapeutics-inc.-2021-05-07
https://www.nasdaq.com/press-release/acasti-pharma-provides-update-on-recent-financing-activities-2021-03-08
https://www.nasdaq.com/press-release/acasti-pharma-announces-results-for-third-quarter-of-fiscal-2021-2021-02-09
https://www.nasdaq.com/press-release/acasti-pharma-provides-update-on-recent-financing-activities-2021-01-27
https://www.nasdaq.com/press-release/acasti-pharma-unaware-of-any-material-change-2020-12-23
https://www.nasdaq.com/press-release/acasti-pharma-provides-business-update-for-the-second-quarter-of-fiscal-2021-2020-11
https://www.nasdaq.com/press-release/acasti-pharma-announces-the-election-of-its-directors-advisory-resolution-approving
https://www.nasdaq.com/press-release/acasti-announces-review-process-of-strategic-alternatives-2020-09-29
https://www.nasdaq.com/press-release/acasti-appoints-seasoned-executive-brian-d.-ford-cpa-ca-as-chief-financial-officer
https://www.nasdaq.com/press-release/acasti-announces-filing-and-mailing-of-information-circular-and-change-in-record-date
https://www.nasdaq.com/press-release/acasti-pharma-reports-topline-triglyceride-results-from-phase-3-trilogy-2-study-of
https://www.nasdaq.com/press-release/acasti-pharma-provides-business-update-for-the-first-quarter-of-fiscal-2021-2020-08
https://www.nasdaq.com/press-release/acasti-pharma-submits-statistical-analysis-plan-to-fda-and-remains-on-track-to-report
https://www.nasdaq.com/press-release/acasti-pharma-provides-fiscal-2020-year-end-business-update-2020-06-29
https://www.nasdaq.com/press-release/acasti-pharma-receives-fda-response-to-trilogy-1-briefing-package-2020-06-19
https://www.nasdaq.com/press-release/acasti-pharma-announces-submission-of-trilogy-1-briefing-package-to-fda-2020-04-30
https://www.nasdaq.com/press-release/acasti-pharma-awarded-notice-of-allowance-for-second-composition-of-matter-patent-in
https://www.nasdaq.com/press-release/acasti-pharma-submits-fda-meeting-request-on-schedule-and-fda-meeting-expected-in-the
https://www.nasdaq.com/press-release/acasti-pharma-awarded-notice-of-allowance-for-additional-composition-of-matter-and
https://www.nasdaq.com/press-release/acasti-receives-nasdaq-notification-regarding-minimum-bid-requirements-2020-02-28
https://www.nasdaq.com/press-release/acasti-pharma-provides-business-update-for-the-third-quarter-of-fiscal-2020-2020-02
https://www.nasdaq.com/press-release/acasti-pharma-schedules-third-quarter-fiscal-2020-and-business-update-conference-call
https://www.nasdaq.com/press-release/acasti-pharma-provides-update-on-trilogy-1-and-trilogy-2-phase-3-trials-of-capre-2020
https://www.nasdaq.com/press-release/acasti-pharma-reports-topline-results-for-trilogy-1-phase-3-trial-of-capre-2020-01-13
https://www.nasdaq.com/press-release/acasti-pharma-provides-update-on-timing-of-topline-results-for-trilogy-1-phase-3
https://www.nasdaq.com/press-release/acasti-pharma-reports-last-patient-visit-in-trilogy-1-phase-3-trial-of-capre-for-the
https://www.nasdaq.com/press-release/acasti-pharma-releases-preliminary-new-animal-data-and-gains-insights-into-capres
https://www.nasdaq.com/press-release/acasti-pharma-provides-business-update-for-the-second-quarter-of-fiscal-2020-2019-11
https://www.nasdaq.com/press-release/acasti-pharma-announces-publication-of-capre-pharmacokinetics-study-in-a-leading-peer
https://www.nasdaq.com/press-release/acasti-pharma-schedules-second-quarter-fiscal-2020-conference-call-2019-11-06
https://www.nasdaq.com/press-release/acasti-pharma-partners-with-aker-biomarine-to-supply-krill-oil-for-caprer-2019-11-04
https://www.nasdaq.com/press-release/acasti-pharma-to-present-at-the-2019-cantor-fitzgerald-global-healthcare-conference
https://www.nasdaq.com/press-release/acasti-pharma-announces-additional-phase-3-milestones-reached-and-remains-on-track-to
https://www.nasdaq.com/press-release/acasti-pharma-receives-funding-from-the-government-of-canada-to-expand-production
https://www.nasdaq.com/press-release/thinking-about-buying-stock-in-aurora-cannabis-acasti-pharma-beyond-meat-aerohive
https://www.nasdaq.com/press-release/acasti-pharma-announces-trilogy-1-trial-has-achieved-100-patient-randomization
https://www.nasdaq.com/press-release/acasti-pharma-announces-publication-capre-bioavailability-study-leading-peer-reviewed
https://www.nasdaq.com/press-release/acasti-pharma-present-2019-spring-investor-summit-new-york-city-april-2nd-2019-04-21
